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Abstract
Background: Chemokines are emerging as important mediators of CNS inflammation capable of activating
leukocyte integrins and directing the migration of leukocyte subsets to sites of antigenic challenge. In this study
we investigated the expression, release and binding of CCL2 (MCP-1) and CCL3 (MIP-1a) in an in vitro model of
the human blood-brain barrier.
Methods: The kinetics of expression and cytokine upregulation and release of the b-chemokines CCL2 and CCL3
were studied by immunocytochemistry and enzyme-linked immunosorbent assay in primary cultures of human
brain microvessel endothelial cells (HBMEC). In addition, the differential binding of these chemokines to the basal
and apical endothelial cell surfaces was assessed by immunoelectron microscopy.
Results: Untreated HBMEC synthesize and release low levels of CCL2. CCL3 is minimally expressed, but not
released by resting HBMEC. Treatment with TNF-a, IL-1b, LPS and a combination of TNF-a and IFN-g, but not IFN-g
alone, significantly upregulated the expression and release of both chemokines in a time-dependent manner. The
released CCL2 and CCL3 bound to the apical and basal endothelial surfaces, respectively. This distribution was
reversed in cytokine-activated HBMEC resulting in a predominantly basal localization of CCL2 and apical distribution
of CCL3.
Conclusions: Since cerebral endothelial cells are the first resident CNS cells to contact circulating leukocytes,
expression, release and presentation of CCL2 and CCL3 on cerebral endothelium suggests an important role for
these chemokines in regulating the trafficking of inflammatory cells across the BBB in CNS inflammation.
Background
The microenvironment of the brain is tightly regulated
by the blood-brain barrier (BBB) the anatomical basis of
which is the cerebral endothelium. The BBB endothe-
lium is highly specialized and different morphologically,
functionally and immunologically from small and large
vessel EC of other organs. Under normal physiological
conditions, the presence of interendothelial tight junc-
tions and absence of a vesicular transport system restrict
the entry of proteins, ions, lipid insoluble non-electro-
lytes and circulating haematogenous cells into the brain
[1,2]. Yet in response to infectious, inflammatory dis-
eases, ischemia, hemorrhage or trauma, there is an
influx of leukocytes to sites of brain damage. Interac-
tions between endothelial cells (EC) and circulating leu-
kocytes have been increasingly implicated in the
initiation and evolution of inflammatory processes in
the central nervous system (CNS). Thus, molecular
changes induced on the endothelium by cytokines lead
to specific interactions with inflammatory cells that
mediate their entry into the brain and accumulation at
sites of antigenic challenge [3].
Chemokines are a family of chemoattractant cytokines
characterized by their unique ability to both recruit and
activate a variety of cell types. Currently, there are about
fifty known chemokine members [4] which are divided
into four sub-families by virtue of highly conserved N-
terminal cysteine motifs (disulfide bonds) and the pre-
sence or absence of intervening amino acids. There are
two major sub-families, which consist of the a-( o r
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Chemokines have been associated with a broad range of
biological and pathological processes [5-7], which
include angiogenesis [8], CNS development [9,10], ather-
osclerosis [11], cancer biology [12-14], autoimmune dis-
eases [15], nervous system inflammation [16], asthma
[17], and haematopoiesis [18].
There is considerable evidence that the b-chemokines
CCL2 (MCP-1) and CCL3 (MIP-1a) play an important
role in CNS inflammation. Several studies have shown
the presence of CCL2 and/or CCL3 in multiple sclerosis
(MS) lesions. In acute MS lesions, CCL2, CCL3 and
CCL4 are selectively expressed by astrocytes, macro-
phages, and microglia in the lesion centre and in the
surrounding white matter, whereas in actively demyeli-
nating plaques CCL5 localizes on EC, perivascular cells
and reactive astrocytes [19]. In acute and chronic active
MS lesions, CCL2, along with CCL7 and CCL8, are
expressed primarily by hypertrophic astrocytes and vari-
ably by inflammatory cells [20,21]. Significantly lower
CSF levels of CCL2 have been reported in MS patients
with active disease compared to controls and patients
with stable MS [22,23]. In this regard, it has been
shown that CCL2 is “consumed” by T lymphocytes and
monocytes as they migrate across brain EC monolayers
in vitro, leading to downregulation of the CCR2 receptor
in response to CCL2, which may account for the
decreased CSF CCL2 levels [24]. The expression of
CCL3 has been associated with microglia and macro-
phages in the white matter lesions of MS patients [25].
In experimental allergic encephalomyelitis (EAE), the
animal model of MS, the onset of the disease coincides
with the mRNA expression of CCL2, CCL3 and other
chemokines [26,27] and the accumulation of CXCL10
and CCL2 [28]. In the Lewis rat model, CCL2 mRNA
increased before the onset of clinical signs, peaked
with height of clinical disease, and declined with reso-
lution [29]. CCL2 expression was localized on lympho-
cytes, macrophages, astrocytes, and EC and correlated
with disease activity [30]. In chronic relapsing EAE,
increased expression of CCL2, CXCL10 and KC was
observed in astrocytes, whereas infiltrating leukocytes
were the source of CCL3 and CCL5 [31]. In the SJL/J
mouse, the expression of CCL3 correlates with the
clinical onset of EAE and administration of anti-CCL3
Abs prevents the development of both acute and relap-
sing disease and infiltration of mononuclear cells into
the CNS initiated by the transfer of neuroantigen pep-
tide-activated T cells [32]. Furthermore, these chemo-
kines could drive Th1/Th2 lymphocyte differentiation
[33]. Vaccination of Lewis rats with naked DNA
encoding CCL2 and CCL3 prevented EAE [34]. These
data suggest that CCL2 and CCL3 have critical and
non-redundant roles in the pathogenesis of autoim-
mune CNS inflammation.
In this study, we investigated the kinetics of expres-
sion and release of CCL2 and CCL3 by resting and cyto-
kine or lipopolysaccharide (LPS) treated human brain
microvessel EC using a well-characterized in vitro
model of the BBB. We show that the constitutive
expression and release of CCL2 by HBMEC is signifi-
cantly upregulated following EC activation in a time-
dependent manner. In contrast, CCL3 expression under
r e s t i n gc o n d i t i o n si sn e g l i g i b l ea n di t sr e l e a s er e q u i r e s
stimulation by cytokines or LPS. Since leukocyte integ-
rin activation by chemokines is required for firm adhe-
sion and transendothelial migration, these findings
further support the active participation of the BBB
endothelium in neuroinflammation.
Methods
Endothelial cell cultures
Human brain microvessel endothelial cells (HBMEC)
HBMEC were isolated from normal brains at autopsy
less than 12 hours post mortem by methods previously
described [35]. The study has complied with all institu-
tional policies and was approved by the ethics commit-
tees of the University of British Columbia and the
Vancouver General Hospital. For these studies we used
HBMEC isolated from five individuals ranging in age
from 30 to 57 years. The cause of death included acute
myocardial infarction (2) and motor vehicle accidents
(3) without CNS involvement. Review of the clinical
records ensured the absence of any pre-existing neurolo-
gical, psychiatric, inflammatory disease or cancer. The
freshly isolated clumps of HBMEC were seeded onto
fibronectin-coated 96 well plates or 100 mm diameter
plastic dishes (Corning Costar Corp., Cambridge, MA)
and maintained in culture in complete media consisting
of M199 supplemented with 10% horse plasma derived
serum (Hyclone Laboratories, Logan, UT), 100 μg/ml
heparin, 20 μg/ml endothelial cell growth supplement,
300 μg/ml glutamine (all from Sigma Chemical Co., St.
Louis, MO) and 1% antibiotic/antimycotic solution (Life
Technologies Inc.). The cells were maintained at 37°C in
a humidified 5% CO2/95% air incubator and culture
media were changed every other day. Endothelial cells
reached confluence 7 to 10 days after plating. The
endothelial origin and purity of the cells was determined
by their strongly positive perinuclear staining for
FVIIIR:Ag and binding of Ulex europeaus I lectin. Pri-
mary cultures from a single isolation were used for each
experiment.
Antibodies and cytokines
For immunocytochemistry, the following primary anti-
bodies (Abs) were used: monoclonal mouse anti-human
CCL2 (10 - 40 μg/ml) and CCL3 (10 - 50 μg/ml) were
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micon International Inc. (Temecula, CA); anti-Factor
VIII related Ag and Ulex europeaus Ab were both pur-
chased from Dako Diagnostics Canada Inc (Mississauga
ON). Secondary Abs used for these studies included the
following: 5 nm gold-conjugated goat anti-mouse IgG
(1:40) (Auroprobe LM GAM IgG) and 10 nm gold-con-
jugated goat anti-mouse IgG (1:20) (Auroprobe EM
GAR IgG, Cedarlane Laboratories Ltd, Hornby, ON).
Mouse anti-human follicle stimulating hormone (FSH)
(BioGenex Laboratories, San Ramon, CA) was used as
irrelevant isotype-matched control Ab. Recombinant
human tumour necrosis factor a (TNF-a) and lipopoly-
saccharide (LPS) were obtained from Sigma Chemical
Co. Recombinant human interferon-g (IFN-g)w a s
obtained from the NIH AIDS Research and Reference
Program. Recombinant human interleukin-1b (IL-1b)
was obtained from Inter Medico (Markham, ON). The
concentrations of cytokines and LPS used were based
on our previous studies and are within the range of con-
centrations reported in the blood and CNS in various
inflammatory and infectious diseases.
Induction of chemokine expression by cytokines and LPS
HBMEC monolayers were grown to confluence in repli-
cate wells and incubated with cytokines for 24, 48 and
72 hrs. The cytokines used were TNF-a (10 - 100 U/
ml), IFN-g (200 - 500 U/ml), IL-1b (10 U/ml), bacterial
LPS (5 μg/ml) and combinations of these cytokines.
Supernatants of cytokine-treated monolayers were col-
lected following the respective time points for detection
of chemokine release by sandwich ELISA.
Reverse transcription PCR (RT-PCR)
Confluent HBMEC cultures grown on 100 mm diameter
fibronectin- coated plates were used untreated or follow-
ing 24 hr incubation with TNF-a (100 U/ml) and IFN-g
(500 U/ml). The cells of both unstimulated and stimu-
lated cultures were removed using a rubber policeman,
centrifuged and the cell pellets were frozen at -70°C.
Trizol (Life Technologies Inc.) was added to the fro-
zen pellet, sonicated and the RNA extracted using
chloroform. The RNA preparation was cleaned up using
an RNeasy kit (Qiagen Inc., Mississauga, ON), according
to the manufacturer’si n s t r u c t i o n s .2-5μgo ft o t a l
RNA was reverse transcribed for 90 min at 37°C using
Moloney Murine Leukaemia Virus reverse transcriptase
(MMLV-RT, USB Corp., Cleveland, OH) and random
hexamer primers (Amersham Pharmacia Biotech Inc.,
Piscataway, NJ). PCR was performed using 2.5 U/25 μl
reaction AmpliTaq Gold (Applied Biosystems, Foster
City, CA) with primers purchased from Life Technolo-
gies Inc. (Table 1) on 1 - 5 μlo fc D N Au n d e rt h ef o l -
lowing conditions: one initial cycle with dissociation at
94°C for 8 min, annealing at 55 - 60°C for 30 sec, exten-
sion at 72°C for 3 min; then cycling at 94°C for 1 min,
55 - 60°C for 30 sec and 72°C for 45 sec on an Applied
Biosystems GeneAmp PCR System 9700 thermalcycler.
GAPDH was used as an internal standard. The following
were used as positive controls: pBluescript-hCCL2 (kind
gift from Dr. Teizo Yoshimura, NCI/NIH, MD) and
pBR322-hCCL3 (kind gift from Dr. Donald Forsdyke,
Queen’s University, Kingston, ON). PCR products were
run on either a 6% polyacrylamide/TBE gel or a 2%
agarose/TBE gel containing ethidium bromide (EtBr)
and visualized under UV light. The RT-PCR experi-
ments were repeated three times for each chemokine
using different primary HBMEC cultures.
Light microscopic intracellular localization of CCL2 and
CCL3
Resting and cytokine treated (TNF-a [10-100 U/ml] and
IFN-g [200-500 U/ml]) confluent monolayers cultivated
in triplicate wells of 96 well plates were washed with
phosphate-buffered saline (PBS) supplemented with 1%
bovine serum albumin (BSA, Sigma Chemical Co.) and
1% normal goat serum (NGS), and then fixed- permea-
bilized using buffered formaldehyde/acetone containing
0.03% Triton X-100 for 10 minutes. The cultures were
then incubated with anti-CCL2 or anti-CCL3 monoclo-
nal Abs diluted at 10 μg/ml in carrier buffer consisting
of PBS containing 5% BSA and 4% NGS. At the end of
the incubation period, cultures were washed and incu-
bated with 5 nm gold-conjugated secondary Ab at 1:40
dilution for 1 hr. Following washing in wash buffer, the
cultures were incubated with silver enhancement solu-
tion (Amersham Life Sciences, Buckinghamshire, Eng-
land) and silver deposition was monitored for 22 - 26
min. Nuclei were counterstained with Giemsa. Controls
included unstimulated HBMEC and cytokine treated
cultures incubated with carrier buffer, isotype-matched
irrelevant Ab (anti-human FSH) or normal mouse IgG
(Cedarlane) instead of primary Abs. The cells were
examined under a Nikon Labophot light microscope.
Immunoelectron microscopy
Confluent unstimulated HBMEC cultures and cultures
treated with TNF-a (10 - 100 U/ml) and IFN-g (200 -
500 U/ml) for 24 hrs were washed with PBS containing
1% BSA and 20 mM NaN3 and incubated with anti-
Table 1 RT-PCR primer sequences
GENE PRIMER SEQUENCE
CCL2 *F: atg aaa gtc tct gcc gcc ctt ctg t
†R: agt ctt cgg agt ttg ggt ttg ctt g
CCL3 F: atg cag gtc tcc act gct gcc ctt
R: gca ctc agc tcc agg tcg ctg aca t
GAPDH F: cca tgt tcg tca tgg gtg tga acc a
R: gcc agt aga ggc agg gat gat gtt c
PCR primer sequences for CCL2 and CCL3 amplify fragments that are 298 and
274 base pairs in length, respectively. *F-forward/sense primer. †R-reverse/
anti-sense primer.
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containing 5% BSA, 4% NGS and 20 mM sodium azide
(NaN3) for 30 min at room temperature. Following
washing in wash buffer, the monolayers were incubated
for 1 hr with the secondary Ab conjugated to 10 nm
gold particles at 1:40 dilution in carrier buffer. Cells
were then washed and fixed with cold 1/2-strength Kar-
novsky’s fixative (2.5% glutaraldehyde and 2% parafor-
maldehyde in 0.2 M sodium cacodylate buffer) for one
hr at 4°C. Following fixation, the cells were washed with
0.2 M sodium cacodylate buffer and post-fixed with 1%
osmium tetroxide for 1 hr at 4°C. After block staining
with uranyl magnesium acetate overnight at 4°C, the
cultures were washed with sodium acetate buffer, dehy-
drated and embedded in Epon-Araldite. Longitudinal
strips cut from the embedded cultures after curing of
the plastic were re-embedded in Araldite for cross sec-
tioning. Thin sections were examined using a Zeiss EM
910 electron microscope. One hundred cells from each
resting or treated cultures were photographed under
25,000× magnification and the number of gold particles
bound per μm of cell membrane on the apical, basal cell
surface or subendothelial matrix was quantified, taking
the magnification into account.
Enzyme-linked immunosorbent assay (ELISA)
HBMEC grown to confluence in triplicate wells of 96
well plates were used untreated or following incubation
with various cytokines or LPS for 24 - 72 hrs. The
supernatants were collected and analyzed by sandwich
E L I S A( Q u a n t i k i n eE L I S AK i t s ,R&DS y s t e m s ,M i n -
neapolis, MN), as per manufacturer’s instructions.
Briefly, culture supernatants and provided standards
were added to microtiter plates coated with the appro-
priate capture Ab. The application of detection Ab,
along with substrate (TMB), allowed color development,
which was stopped with 2N sulfuric acid. Absorbance
was read with an ELISA microtiter plate reader at a
wavelength of 490 nm. The assay sensitivity was <5 pg/
ml for CCL2 and <10 pg/ml for CCL3. The generation
of a standard curve using chemokine standards allowed
the calculation of the quantity of chemokines released
by HBMEC in the culture supernatants.
Statistical analysis
Values derived from ELISA experiments were analyzed
using analysis of variance (ANOVA) to determine signif-
icant differences between treatments. Student’stt e s t s
were used where differences were found. The Tukey test
was also used as a multiple comparison method. Data
that were not normally distributed were subjected to
Kruskal-Wallis ANOVA on Ranks and Mann-Whitney
U-tests. The chi-square test was used to analyze the
immunoelectron microscopy data. Significant differences
between cytokine treated cells and control groups are
shown as (*) where p < 0.05.
Results
Detection of CCL2 and CCL3 RNA by RT-PCR
RNA extracted from confluent monolayers of HBMEC
with and without treatment with 100 U/ml TNF-a and
500 U/ml IFN-g for 24 hrs was used to study the
expression patterns of CCL2 and CCL3 in these cul-
tures. The CCL2 and CCL3 gene-specific primers (Table
1) used for these studies amplified 298 and 274 base
pair fragments, respectively. The expression of CCL2
RNA from both unstimulated and stimulated HBMEC
was similar (Fig. 1A). There appeared to be no detect-
able upregulation of RNA expression following cytokine
treatment. CCL2 cDNA cloned into pBluescript was
used as the positive control in these experiments.
CCL3 RNA was found in barely discernible levels in
unstimulated HBMEC (Fig. 1B). Incubation with 100 U/ml
TNF-a and 500 U/ml IFN-g for 24 hrs resulted in increase
in RNA expression. The control used for these experi-
ments was CCL3 cDNA cloned into a pBluescript vector.
Immunocytochemistry
Immunogold silver staining was used to demonstrate
intracellular CCL2 and CCL3 protein expression in con-
fluent monolayers of unstimulated HBMEC and in cul-
tures treated for 24 to 72 hrs with TNF-a,I F N - g,I L - 1 b
and LPS, or combinations of TNF-a and IFN-g.A l l
untreated cells exhibited positive staining for CCL2 in
the form of fine, black, granular cytoplasmic deposits
(Fig. 2A) indicating constitutive protein expression con-
sistent with the constitutive RNA expression by RT-
PCR. Treatment with cytokines or LPS resulted in
increased diffuse cytoplasmic staining in the majority of
Figure 1 RNA expression of CCL2 (A) and CCL3 (B) by HBMEC
determined by semi-quantitative RT-PCR. Increasing amounts of
RNA (not shown) were used to detect differential expression in
unstimulated HBMEC and cells treated with 100 U/ml TNF-a and
500 U/ml IFN-g for 24 hrs. After amplification with gene-specific
primers, CCL2 or CCL3 and GAPDH PCR samples were run on a 2%
agarose gel after 35 and 25 cycles respectively, under the following
conditions: pre-PCR step (94°C for 8 min, 55 - 60°C for 30 sec and
72°C for 3 min) and cycling (94°C for 1 min, 55 - 60°C for 30 sec
and 72°C for 45 sec). The data shown are from one of three
experiments for each chemokine with similar results.
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Some variation in the intensity of staining between indi-
vidual cells in both resting and stimulated cultures was
usually present (Figs. 2A-D), however, no differences
were detected between HBMEC from different donors.
Unstimulated HBMEC monolayers showed uniformly
slight cytoplasmic staining for CCL3 indicating minimal
protein expression at all time points investigated (Fig.
3A) consistent with the low RNA expression by RT-
PCR. Incubation with TNF-a,I F N - g,I L - 1 b and LPS, or
combination of TNF-a and IFN-g resulted in increased
intensity of cytoplasmic staining in all cells, with some
variation between EC of the same culture (Figs. 3B-D),
but not between different donor endothelial cells.
Release of CCL2 and CCL3 by HBMEC in culture
In order to determine the amount of CCL2 and CCL3
released by confluent HBMEC monolayers treated with
TNF-a,I F N - g,I L - 1 b, LPS, or combination of TNF-a
and IFN-g, culture supernatants from both resting and
stimulated cultures grown in triplicate wells were
removed at 24, 48 and 72 hrs post stimulation and ana-
lyzed by sandwich ELISA. Unstimulated HBMEC
r e l e a s e d1 0~ 2 1n g / m lo fC C L 2o v e r2 4-7 2h r sw i t h
significant increase in release following cytokine treat-
ment in a time-dependent fashion (Fig. 4A). Treatment
with TNF-a at 10 or 100 U/ml increased CCL2 release
up to ~35 ng/ml at 24 hrs and up to a maximum of
~63 ng/ml at 72 hrs. This increase in CCL2 release was
time-, but not concentration-dependent. Incubation with
LPS (5 μg/ml) or IL-1b (10 U/ml) resulted in 124% and
156% increase in CCL2 release over unstimulated cul-
tures, respectively, in a time-, but not concentration-
dependent manner. Incubation of HBMEC with IFN-g
alone resulted in a modest, but not significant upregula-
tion of release that was similarly time- but not concen-
tration- dependent. Co-incubation with TNF-a (100 U/
ml) and IFN-g (200 U/ml) augmented CCL2 release to
levels comparable with TNF-a treatment alone.
Figure 2 Intracellular localization of CCL2 in HBMEC by immunogold silver staining. (A) Unstimulated HBMEC constitutively express CCL2
as shown by the positive cytoplasmic staining in the form of fine, granular black deposits of silver-enhanced gold particles. Nuclei are
counterstained with Giemsa. (B)-(D) The intensity of staining is markedly increased following incubation with (B) TNF-a (10 U/ml) for 48 hrs, (C)
IL-1b (10 U/ml) for 72 hrs and (D) LPS (5 μg/ml) for 48 hrs. (E) Control cultures incubated with secondary antibody only show no staining. Scale
bars = 50 μm.
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HBMEC was measured by ELISA in culture superna-
tants similarly collected at 24, 48 and 72 hr time points.
Unstimulated cells did not release any detectable protein
(Fig. 4B). Stimulation with 100 U/ml TNF-a resulted in
small amounts of protein release within the first 24 hrs
and up to 100 pg/ml over 48 and 72 hrs. Lower concen-
trations of TNF-a ( 1 0U / m l ) ,a sw e l la sI F N - g at 200
and 500 U/ml, failed to induce CCL3 release into the
media. However, co-incubation of HBMEC with TNF-a
(100 U/ml) and IFN-g (200 U/ml) significantly augmen-
ted CCL3 release to a maximum of 200 pg/ml (p <
0.005) in a time-dependent manner. Treatment of the
monolayers with IL-1b (10 U/ml) or LPS (5 μg/ml)
induced the release of up to 200 - 400 pg/ml of this
chemokine. There were some quantitative differences in
the constitutive and stimulated release of both chemo-
kines between HBMEC from different donors; however,
the pattern of chemokine release after cytokine or LPS
treatment was similar in all experiments.
Differential binding of CCL2 and CCL3 to the surface of
HBMEC
Chemokines are secreted molecules that exert their
actions via binding to glycosaminoglycans at the
endothelial surface and the extracellular matrix. In order
to elucidate the binding patterns of CCL2 to the cell
membrane, an immunoelectron microscopic approach
was employed. An additional advantage of this method
is the ability to visualize both the apical and basal bind-
ing of the chemokines. HBMEC cultures were used
Figure 3 Intracellular localization of CCL3 in HBMEC by immunogold silver staining. (A) In untreated cultures, cytoplasmic staining is faint
indicating minimal constitutive expression. Nuclei are counterstained with Giemsa. (B)-(D) The density of the granular black cytoplasmic deposits
is increased in cultures treated with (B) TNF-a (100 U/ml)+ IFN-g (200 U/ml) for 72 hrs, (C) IL-1b (10 U/ml) for 72 hrs and (D) LPS (5 μg/ml) for 48
hrs. (E) Control cultures incubated with secondary antibody only show no staining. Scale bars = 50 μm.
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Page 6 of 12Figure 4 Quantitation of CCL2 and CCL3 release by resting and cytokine stimulated HBMEC by ELISA. (A) Detection of CCL2 protein in
supernatants of HBMEC cultures under resting conditions and following incubation with cytokines and LPS. Chemokine release was determined
by sandwich ELISA at the indicated time intervals. Values represent mean release (pg/ml) ± SEM (n = 3). Tukey test p ≤ 0.001; * p < 0.05 as
compared to unstimulated HBMEC. Values shown represent one of two independent, representative experiments. (B) Detection of CCL3 protein
in supernatants of resting HBMEC cultures and monolayers treated with cytokines and LPS. Chemokine release was determined by sandwich
ELISA at the indicated time intervals. Values represent mean release (pg/ml) ± SEM (n = 3). ANOVA p ≤ 0.001; * p < 0.05 as compared to
unstimulated HBMEC. Values shown are the results of one of two independent, representative experiments.
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(100 U/ml TNF-a +5 0 0U / m lI F N - g). A small number
of gold particles indicating the presence of CCL2 were
associated with the cell surface of untreated HBMEC
(Fig. 5A). Most of the gold particles were associated
with the apical cell surface compared to the basolateral
surface, although this difference did not reach significant
difference (Fig. 5C). In cytokine-treated monolayers,
CCL2 was redistributed and bound preferentially to the
basal cell surface and the discontinuous, amorphous,
basal lamina-like material underlying the basal surface
compared to the apical one, as shown by the increased
mean value (Figs. 5B, C). The number of gold particles
bound to the basal cell surface was significantly greater
in cytokine treated versus resting HBMEC (Fig. 5C).
Gold particles were not observed along intercellular
contacts. In contrast to CCL2, virtually no gold particles
were identified on the apical cell surface, and only occa-
sional gold particles, indicating the presence of CCL3,
were bound to the basal cell surface of unstimulated
HBMEC (Figs. 5D, F). Gold particles were not found
along intercellular contacts. Upon cytokine treatment,
Figure 5 Surface localization of CCL2 and CCL3 by immunoelectron microscopy. (D, E) Surface localization of CCL2 on HBMEC by
immunoelectron microscopy. (A) In resting monolayers, gold particles indicating the presence of CCL2 are bound mostly to the apical cell surface
(arrow). (B) In cultures treated with TNF-a (100 U/ml) + IFN-g (500 U/ml) for 24 hrs gold particles are preferentially bound to the subendothelial
basal lamina-like material (arrows). Arrowheads in (A) and (B) indicate the basal cell surface. Scale bars = 0.25 μm. (C) Quantification of the number
of gold particles bound to the apical and basal cell surface of unstimulated HBMEC shows no significant difference between apical and basal
binding (p ≥ 0.1). In cytokine-treated HBMEC cultures, there is a significant increase in the number of gold particles bound to the basal cell surface
and the basal lamina-like material versus the apical surface (p ≤ 0.01). The number of gold particles at the basal cell surface is significantly greater in
activated versus resting HBMEC (p ≤ 0.01). (D, E) Surface localization of CCL3 on HBMEC by immunoelectron microscopy. (A) In resting monolayers
occasional gold particles are bound to the basal cell surface only (arrow). (B) Following treatment with TNF-a (100 U/ml) + IFNg (500 U/ml) for 24
hrs gold particles are preferentially bound to the apical surface (arrow). Arrowheads in (A) and (B) indicate the basal cell surface. Scale bars = 0.25
μm. (F) Quantification of the number of gold particles bound to the apical and basal cell surfaces of unstimulated and cytokine-treated HBMEC
cultures shows no statistically significant differences between the different groups (p ≥ 0.15).
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face, whereas the number of gold particles associated
with the basal cell surface remained the same. Thus,
although binding to the basal surface was similar
between untreated and treated HBMEC, the mean num-
ber of gold particles associated with the apical surface
was greater in cytokine activated cells (Figs 5E, F).
Discussion
The entry of inflammatory cells into the brain is a criti-
cal event in the pathogenesis of inflammatory and infec-
tious diseases, as well as non-inflammatory conditions
of the CNS, such as stroke and trauma. As an anatomi-
cal and immunological barrier, the BBB plays a central
role in the recruitment of leukocytes in acute and
chronic CNS inflammation. It is now well established
that the transendothelial movement of leukocytes is a
multi-step process, each step being mediated by specific
interactions between EC adhesion molecules and their
ligands on leukocytes [36]. Some of the molecular
mechanisms involved in the trafficking of leukocytes
across the BBB have been recently elucidated and
involve membrane interactions between adhesion mole-
cules induced on cerebral EC by inflammatory media-
tors and integrins or glycosylated ligands on leukocytes.
Recent studies from this laboratory have shown that the
adhesion and transendothelial migration of resting and
activated T lymphocytes across the BBB depend upon
the activation status of the endothelium and the T cells
and are mediated by receptor-ligand interactions that
are specific for each step and for each class of leuko-
cytes [37,38].
In vivo and in vitro studies have established a critical
role for chemokines in the leukocyte adhesion cascade.
Binding of chemokines to their G-protein coupled
receptors on leukocytes triggers inside-out signaling
leading to rapid integrin activation and firm adhesion to
the endothelium [39]. Although the expression of che-
mokines by glial cells in the CNS has been relatively
well documented [21,40], human cerebrovascular che-
mokine expression has not been fully characterized. In
the present study we show that CCL2 is constitutively
expressed by HBMEC with marked increase of the intra-
cellular protein and a 3-fold increase in the release of
CCL2 into the media following treatment with TNF-a,
IL-1b and LPS. Although IFN-g alone had no effect on
CCL2 release by HBMEC, combination of the highest
concentrations of TNF-a and IFN-g resulted in a 3-fold
increase of the CCL2 levels in the supernatants.
Constitutive expression of CCL2 mRNA has been pre-
viously reported in porcine brain EC with upregulation
upon stimulation with TNF-a [41]. In vitro studies
using rat brain and retinal EC lines showed constitutive
expression of CCL2 and increased release into the
media following activation with TNF-a, IL-1b and IFN-g
[42]. Both the constitutive release at 2,000 - 2,700 pg/ml
and the stimulated release at 5,500 pg/ml were much
lower compared to HBMEC (up to 20,000 pg/ml and
60,000 pg/ml, respectively), which may reflect species
differences in CCL2 expression and release. In extracer-
ebral endothelium models, CCL2 RNA transcripts have
been demonstrated in human aortic, pulmonary artery
and umbilical vein endothelial cell (HUVEC) cultures, as
well as in freshly removed human arteries and veins
[43]. Expression of CCL2 mRNA has been detected in
resting and cytokine activated HUVEC and human brain
EC after IFN-g stimulation [44]. Exposure of human cer-
ebrovascular EC to hypoxic astrocyte-conditioned media
for 4 - 8 hrs increased the release of CCL2 from a low
constitutive level of 100 pg/ml to a modest 600 - 700
pg/ml, both significantly lower than the levels obtained
in the present study [45]. This may be related to the
short time of exposure to hypoxic media. Similarly,
expression of CCL2 was induced in human brain-
derived EC by endothelin-1 and ischemia [46]. A modest
increase in CCL2 release, up to 1,800 pg/ml, has been
reported in a human brain EC line after incubation with
heat-killed Streptococcus suis [47]. The same strain had
no effect on CCL2 expression by HUVEC. In addition
to cytokines, injection of the HIV Tat1-72 protein into
the mouse hippocampus was shown to increase the
expression of CCL2 on brain vascular endothelium [48].
Substantial evidence indicates the importance of CCL2
in the induction and propagation of the inflammatory
cascade. Thus, CCL2 was shown to stimulate T cell
migration across microvascular endothelium [49] and to
mediate the firm adhesion of monocytes under flow
conditions [50]. In the CNS, knockout models for CCL2
and CCR2 provide strong evidence for the importance
of the CCL2-CCR2 interaction [51,52]. Recent observa-
tions indicate that glia-derived CCL2 regulates the
development of EAE by attracting TNF-a and iNOS-
producing dendritic cells and macrophages to the CNS
[53]. Furthermore, a recent study investigating potential
mechanisms for HIV entry into the CNS indicates that
CCL2 enhances the transmigration of HIV-infected leu-
kocytes across the BBB via the upregulated expression
of CCR2 [54].
In contrast to CCL2, the constitutive RNA and protein
expression of CCL3 by HBMEC is negligible. Further-
more, resting HBMEC do not constitutively release
CCL3 into the media. Treatment with TNF-a and IFN-g
increased RNA expression and incubation with indivi-
dual cytokines or LPS upregulated protein expression
and induced CCL3 release. However, under identical
experimental conditions, the stimulated CCL2 release
was typically two orders of magnitude greater than
CCL3 release. IFN-g alone has no effect on cerebral
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with TNF-a, a synergistic effect resulted in higher pro-
tein levels compared to TNF-a alone. Expression of
CCL3 by EC has been addressed in a limited number of
studies. In animals, CCL3 has been reported in murine
bone marrow EC [55] and in the endothelium of epi-
neurial and endoneurial vessels following transection of
the rat sciatic nerve [56]. Furthermore, expression of
this chemokine was induced in a murine endothelial cell
line by alloantigen-primed T cells [57]. In humans,
endothelial expression of CCL3 has been documented in
HUVEC incubated with activated platelets [58] or
exposed to diamide [59] and LPS [60]. In addition,
CCL3 has been localized to EC of blood vessels and
splenic sinusoids in the hemophagocytic syndrome [61].
According to a recent report, transmigration of bone
marrow-derived dendritic cells across mouse brain EC
monolayers was increased in the presence of CCL3 con-
centration gradients [62]. The expression of CCL3 by
cerebrovascular endothelium under resting and inflam-
matory conditions has not been previously addressed.
It is now well established that immobilization of che-
mokines by binding to glycosaminoglycans on the lumi-
nal EC surface enhances leukocyte adhesion, while
binding to the abluminal surface and subendothelial
matrix promotes their directional migration to sites of
inflammation [63]. The present study shows that, follow-
ing their release into the culture media, CCL2 and CCL3
bind to the surface of HBMEC and to the discontinuous
basal lamina-like material under the basal cell surface in
a polarized manner, which is distinct for each chemokine.
Thus, under resting conditions, CCL2 binds preferentially
to the apical (luminal) surface of HBMEC, whereas CCL3
shows minimal binding only to the basal (abluminal) EC
surface, which is consistent with our protein synthesis
and release results. In cytokine activated HBMEC, bind-
ing of CCL2 is redistributed towards the basal cell surface
and that of CCL3 preferentially on the apical surface.
These findings suggest that CCL3 may be primarily
responsible for the initial recruitment and activation of
CCR1 and/or CCR5 expressing cells, whereas CCL2 plays
a greater role in establishing the chemotactic gradients
necessary for the directional cell migration into the brain
parenchyma. In accordance with these observations, pre-
vious studies have demonstrated the presence of specific
and separate binding sites for CCL2 and CCL3 along the
abluminal surface of human brain microvessels [64]. The
differential binding of CCL2 and CCL3 to cerebral EC in
an inflammatory milieu lends support to previous studies
which, taking into account the CCL2 and CCL3 expres-
sion patterns and Ab therapy studies, suggest that CCL3
controls mononuclear cell accumulation during acute
EAE, whereas CCL2 controls cellular infiltration during
relapsing disease indicating that acute and relapsing EAE
are regulated by the differential expression of CCL2 and
CCL3 [65].
Previous in vitro studies from this laboratory have
documented the expression and cytokine upregulation of
the b-chemokines CCL4 and CCL5 by HBMEC [66] and
their role in enhancing adhesion of memory and acti-
vated CD4+ T lymphocytes to cytokine treated HBMEC
[67]. The present study points towards substantial differ-
ences in cytokine regulation of protein release among the
four b-chemokines. The release of CCL2 and CCL3 is
upregulated by TNF-a,I L - 1 b, LPS and TNF-a +I F N - g,
but not IFN-g alone, in contrast to CCL5 which responds
to TNF-a,I F N - g and LPS, but not IL1-b. The release of
CCL4 is augmented by LPS and combinations of TNF-a
with IFN-g or IL-1b, but not by single cytokine treat-
ments. Overall, the release of CCL2 under resting and sti-
mulated conditions is much greater than that of CCL3,
CCL4 and CCL5. Additional differences exist in the dis-
tribution of bound chemokines to HBMEC. In resting
monolayers, CCL2 and CCL5 are bound preferentially to
the apical EC surface, CCL4 to both apical and basal sur-
faces and CCL3 only to the basal surface. Upon cytokine
stimulation, this polarized expression is reversed for all
four chemokines, with CCL2, CCL4 and CCL5 now pre-
sent preferentially along the basal surface and suben-
dothelial matrix, and CCL3 distributed mostly along the
apical surface. These differences strongly suggest differ-
ential and possibly temporal roles of these chemokines in
the regulation of leukocyte transendothelial migration in
CNS inflammation.
Conclusions
The studies reported herein demonstrate that brain
microvessel EC synthesize CCL2 and CCL3 with signifi-
cant upregulation after cytokine and LPS activation. The
constitutive and stimulated production and release of
CCL2 is quantitatively greater compared to CCL3. The
polarized distribution of these chemokines on HBMEC
under resting and simulated inflammatory conditions
points towards possibly distinct functions, with CCL3
on the apical surface promoting leukocyte adhesion
through integrin activation and CCL2 on the basal sur-
face directing their migration across the BBB. These
findings further emphasize the important role played by
the cerebral microvascular endothelium in regulating
inflammatory responses at the BBB.
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